BrightMeds' money-back guarantee includes a clause stating the guarantee no longer applies if the company "is unable to provide the GLP-1 product due to reasons such as the FDA no longer supporting its manufacturing, unavailable raw materials, or legal action." This language acknowledges the regulatory risk directly
doi: 10.3389/fphar.2023.1267765 Received 27 July 2023 Accepted 09 October 2023 Published 13 November 2023 Volume 14 - 2023 Edited by Xinwang Yang, Kunming Medical University, China Reviewed by Yipeng Wang, Soochow University, China Lin Wei, Anhui Medical University, China Updates Copyright 2023 He, Wang and Qu
KRAS signalling has been linked to enhanced mitochondrial metabolism by various mechanisms in colorectal, lung and pancreatic cancers 8,18 , as has APC and p53 (refs
Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Soderlund S, Stahlman M, et al